Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Enzyme Inhib Med Chem ; 38(1): 2220084, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37318308

ABSTRACT

Boronic acids/esters have recently emerged in the field of medicinal and pharmaceutical research due to their exceptional oxophilicity, low toxicity, and unique structure. They are known as potent enzyme inhibitors, cancer therapy capture agents, and can mimic certain types of antibodies to fight infections. They have been designed and developed into drugs, and this approach has emerged in the last 20 years. Five boronic acid drugs have been approved by the FDA and Health Canada, two of which are used to treat cancer, specifically multiple myeloma. The purpose of this review is to investigate boronic acid/ester derivatives as potential pharmaceutical agents as well as the mechanism of action. It will concentrate on six types of cancer: multiple myeloma, prostate cancer, breast cancer, lung cancer, cervical cancer, and colon cancer. Some newly developed boron-containing compounds have already demonstrated highly promising activities, but further investigation is required before final conclusions can be drawn.


Subject(s)
Multiple Myeloma , Prodrugs , Humans , Prodrugs/pharmacology , Prodrugs/chemistry , Esters/chemistry , Multiple Myeloma/drug therapy , Boronic Acids/pharmacology , Boron Compounds/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...